In vivo engraftment of in situ gene-edited HSPCs
| Donor . | Donor cell no. (×1000) . | Donor-derived chimerism in the blood (12 week), % . | No. of successful granulocyte donor chimerism/total . | Donor-derived HSPC chimerism (BM), % . | No. of successful HSPC donor chimerism/total . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Total . | B cell . | T cell . | Macrophage . | Granulocyte . | |||||
| tdTomato+ | 10 | 48.3 | 92 | 68 | 32.9 | 16.4 | 5/6 | 78.6 | 5/6 |
| 7.8 | 92.9 | 99.5 | 99.9 | 96.6 | 90.7 | 94.5 | |||
| 11 | 52 | 93.7 | 95.5 | 32.7 | 19.9 | 20.4 | |||
| 5 | 16.2 | 97.7 | 89.4 | 1.38 | 0.22 | 0.064 | |||
| 5 | 39.6 | 93.8 | 74.1 | 12.5 | 2.96 | 27.1 | |||
| 5 | 81.2 | 98.8 | 91.7 | 12.6 | 1.88 | 6.76 | |||
| tdTomato− | 10 | 10.8 | 79.6 | 74.5 | 0.98 | 0.75 | 1/5 | 0.14 | 0/4 |
| 8.9 | 9.05 | 91.2 | 95.7 | 0.21 | 0.11 | 0.23 | |||
| 5 | 4.11 | 8.74 | 71.5 | 0.14 | 0.034 | 0 | |||
| 5 | 20.9 | 96.6 | 61.5 | 0.64 | 0.19 | 0 | |||
| 5 | 7.72 | 91.2 | 88.9 | 0.15 | 0.29 | nd | |||
| “High donor number” tdTomato− | 30 | 74.9 | 98.5 | 95 | 14.9 | 4.63 | 4/4 | 29.2 | 3/4 |
| 17.7 | 77.4 | 99.5 | 99.2 | 41.6 | 18.2 | 45.4 | |||
| 15 | 61.8 | 99.4 | 95.7 | 7.04 | 7.62 | 13.4 | |||
| 15 | 19.9 | 91.3 | 92.2 | 0.26 | 0.48 | 0 | |||
| Donor . | Donor cell no. (×1000) . | Donor-derived chimerism in the blood (12 week), % . | No. of successful granulocyte donor chimerism/total . | Donor-derived HSPC chimerism (BM), % . | No. of successful HSPC donor chimerism/total . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Total . | B cell . | T cell . | Macrophage . | Granulocyte . | |||||
| tdTomato+ | 10 | 48.3 | 92 | 68 | 32.9 | 16.4 | 5/6 | 78.6 | 5/6 |
| 7.8 | 92.9 | 99.5 | 99.9 | 96.6 | 90.7 | 94.5 | |||
| 11 | 52 | 93.7 | 95.5 | 32.7 | 19.9 | 20.4 | |||
| 5 | 16.2 | 97.7 | 89.4 | 1.38 | 0.22 | 0.064 | |||
| 5 | 39.6 | 93.8 | 74.1 | 12.5 | 2.96 | 27.1 | |||
| 5 | 81.2 | 98.8 | 91.7 | 12.6 | 1.88 | 6.76 | |||
| tdTomato− | 10 | 10.8 | 79.6 | 74.5 | 0.98 | 0.75 | 1/5 | 0.14 | 0/4 |
| 8.9 | 9.05 | 91.2 | 95.7 | 0.21 | 0.11 | 0.23 | |||
| 5 | 4.11 | 8.74 | 71.5 | 0.14 | 0.034 | 0 | |||
| 5 | 20.9 | 96.6 | 61.5 | 0.64 | 0.19 | 0 | |||
| 5 | 7.72 | 91.2 | 88.9 | 0.15 | 0.29 | nd | |||
| “High donor number” tdTomato− | 30 | 74.9 | 98.5 | 95 | 14.9 | 4.63 | 4/4 | 29.2 | 3/4 |
| 17.7 | 77.4 | 99.5 | 99.2 | 41.6 | 18.2 | 45.4 | |||
| 15 | 61.8 | 99.4 | 95.7 | 7.04 | 7.62 | 13.4 | |||
| 15 | 19.9 | 91.3 | 92.2 | 0.26 | 0.48 | 0 | |||
Donor-derived chimerism in the peripheral blood and BM of NSG recipients that received transplantation with the indicated number of tdTomato+ or tdTomato− LinloKit+ HSPCs from Ai9;SpCas9-EGFP animals previously injected with 5 × 1012 vg per animal scAAV encoding targeting gRNAs. Donors are grouped into equal donor cell number (at ∼7000 donor cells) tdTomato+ or tdTomato− source; the “high donor number” condition, averaging 20 000 donor cells (for tdTomato− donor source only), was included to provide functional assessment of the higher frequency of phenotypic HSCs in tdTomato+ LinloKit+, compared with tdTomato− counterparts (Figure 2B). Blood chimerism 12 weeks after transplant is shown for the following populations: total (CD45+), B cell (B220+), T cell (CD3+), macrophage (CD3−B220−CD11b+), granulocyte (CD3−B220−CD11b+Gr1+). Percent donor-derived HSPCs (LinloKit+CD150+CD48−) is also shown for individual animals. “Successful engraftment” is determined as outlined in supplemental Methods and displayed in bold font.
nd, not determined.